Amneal Pharmaceuticals, Inc. research snapshot
AMRX AI stock analysis as of August 3, 2026 views Amneal Pharmaceuticals as a mid-cap generic drug maker with improving momentum after a strong Q2. Second quarter revenue rose 10% year over year to $796.2 million and adjusted diluted EPS of $0.30 beat the $0.23 consensus, prompting management to raise full-year 2026 guidance for a second time. The company also repriced its $2.084 billion term loan to cut interest costs and is set to add a biosimilars vertical through the pending Kashiv BioSciences acquisition. At the July 31 close of $18.32, the stock carries a market cap of about $5.84 billion, trades near 18x forward EPS, and is up roughly 127% over the past year, so the valuation already prices in much of the turnaround. This AMRX AI stock forecast uses scenarios, not a precise price prediction, and is for informational use only, not investment advice.
Current price
$18.32 close on July 31, 2026
Market cap
$5.84 billion verified market cap, using the July 31 price times 319.02M shares
AI score
62 / 100
Rating
Improving fundamentals after a Q2 2026 earnings beat and a second guidance raise, offset by an extended valuation after a roughly 127% one-year rally and a large net debt position
Trend status
At $18.32, above the 50-day moving average near $16.06 and below the 52-week high of $19.26, with a 52-week range of $7.66 to $19.26 and a YTD gain of about 45%
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Amneal develops, manufactures, and distributes generics, complex injectables, biosimilars, and specialty branded drugs through its Affordable Medicines, Specialty, and AvKARE segments, serving retail, institutional, and government customers mainly in the US. | Medium |
| Moat | Moderate. Manufacturing scale, a portfolio of about 300 complex generic and specialty products, FDA-approved facilities, regulatory expertise, and branded neurology franchises (CREXONT, Rytary, UNITHROID) create barriers, but generic competition erodes pricing power over time. | Medium |
| Management | Founder co-CEOs Chirag and Chintu Patel lead the company with President Gregory Divis. Recent capital decisions include a second FY2026 guidance raise, a term loan repricing that saves about $12 million a year, and the pending Kashiv BioSciences acquisition to enter biosimilars. | Medium |
| Financial trend | Revenue grew from $2.39B in FY2023 to $3.02B in FY2025. Q2 2026 revenue rose 10% to $796.2M, adjusted EBITDA rose 12% to $206M, and GAAP net income attributable to Amneal increased 157% to $58M. H1 2026 revenue reached $1,518.7M with $119.9M in attributable net income. | High |
| Valuation | At $18.32, the trailing PE is about 38x and the forward PE is about 18x based on the FY2026 adjusted EPS guide of $0.96 to $1.06. EV is about $8.5 billion with an EV/EBITDA near 13x, moderate for the forward story but not cheap after the 127% one-year rally. | Medium |
| Technical trend | The July 31 close of $18.32 is about 14% above the 50-day moving average of $16.06, well above the 200-day moving average of $13.48, and below the 52-week high of $19.26 set on July 29. RSI near 61 shows positive but not extreme momentum after an earnings-day fade. | Medium |
| Risk level | Key risks include net debt of about $2.6 billion, generic pricing pressure, Kashiv acquisition and integration execution, potential dilution toward 340 million diluted shares, FDA and biosimilar launch risk, customer concentration, tariffs, and an active securities investigation announcement from July 2026. | Medium-high |
| AI confidence | High confidence in reported Q2 2026 and H1 2026 financials and guidance, medium confidence in forward scenarios. The 127% one-year rally means the re-rating is substantially priced in and future upside depends on execution beyond current estimates. | Medium-high data confidence |
| Investment certainty | The bull case requires biosimilars to ramp on plan, leverage to fall below 3.0x by 2028, and margins to hold while generic pricing declines. Q3 2026 earnings, the Kashiv close, and debt repricing completion are the near-term confirmation points. | Medium |
AMRX AI stock forecast
The AMRX AI stock forecast starts from the July 31, 2026 close of $18.32 and uses the raised FY2026 adjusted EPS guidance of $0.96 to $1.06 plus the FY2027 consensus of about $1.16 as the earnings baseline. Scenario ranges below are illustrative bands driven by forward earnings assumptions and valuation multiples, not promised prices.
$24 to $30
More likely if the Kashiv biosimilars acquisition closes and ramps above plan, adjusted EPS reaches $1.20 or higher, leverage falls below 3.0x ahead of schedule, specialty brands keep double-digit growth, and the market awards a forward PE of 20x to 22x.
$18 to $22
More likely if FY2026 guidance is maintained or modestly raised, Kashiv integrates on schedule, adjusted EPS settles near $1.00 to $1.10, generic pricing declines stay manageable, and the forward PE holds in the 16x to 20x range.
$12 to $15
More likely if generic pricing accelerates, the biosimilars deal is delayed or proves dilutive, interest costs stay elevated despite the repricing, margins compress, or the market re-rates the stock below 14x forward earnings.
AMRX AI technical analysis
AMRX AI technical analysis with a July 31, 2026 data cutoff shows the stock at $18.32, above its 50-day moving average of about $16.06 and its 200-day moving average of about $13.48. The stock rallied from a 52-week low of $7.66 to a high of $19.26 on July 29, then pulled back on the Q2 earnings reaction, closing at $18.32 on July 31. RSI near 61 indicates positive momentum without extreme overbought readings.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $18.32 | July 31, 2026 closing reference used for valuation and market-cap calculations. |
| Immediate support | $17.65 to $17.90 | The July 30 earnings-day low and the early-July consolidation zone are the first support area. |
| Primary support | $16.00 to $16.06 | The 50-day moving average near $16.06 and the round $16.00 level are the main trend-support reference. |
| Near resistance | $19.10 to $19.26 | The July 29 close of $19.10 and the 52-week high of $19.26. A confirmed close above this zone opens higher targets. |
| Overhead resistance | $21 to $23 | The Goldman Sachs target of $21 and the UBS target of $23 align with round-number resistance above the high. |
| Moving averages | 50-day near $16.06, 200-day near $13.48 | Price above both averages signals a bullish trend structure, with the wide 50/200 spread reflecting strong momentum. |
| Momentum | RSI near 61 | Momentum is positive but has cooled from overbought levels after the earnings-day fade. |
| Volume | Average volume about 1.85M shares over 20 days | Volume rose to 2.0M to 2.5M shares around the Q2 earnings release. Watch volume confirmation at a retest of the $19.26 high. |
| Volatility | 52-week range $7.66 to $19.26, beta 1.26 | The wide range reflects the fundamental turnaround. Expect continued volatility around earnings, FDA, and biosimilar news. |
| Invalidation | Sustained close below $16.00 | A break below the 50-day moving average and the $16.00 level would suggest the uptrend has paused and warrants a thesis review. |
AMRX AI trading strategy
This AMRX AI trading strategy is a rules-based research framework, not personalized advice. It connects price action with generic and specialty revenue, adjusted EPS, net debt, leverage reduction, and biosimilar pipeline events.
Monitor for a confirmed close above the $19.26 52-week high with volume above the 20-day average, alongside confirmation that Q3 2026 earnings, the Kashiv biosimilars close, and the debt repricing completion support the raised guidance.
A failed breakout or a close below $17.90 should reduce confidence. Reassess if margins disappoint, biosimilar integration slips, or debt reduction stalls.
If AMRX pulls back toward the $16.00 to $16.60 range where the 50-day moving average sits while the fundamental thesis (Q2 beat, raised guidance, debt repricing) stays intact, compare the pullback price with the forward PE of about 18x and EV/EBITDA near 13x before assessing value.
Do not buy a pullback solely on price. A deterioration in generic pricing, higher-than-expected dilution, or biosimilar delays can make a lower price less attractive rather than a bargain.
Track key catalysts: completion of the term loan repricing (expected early August 2026), the Kashiv BioSciences acquisition close and additional $350M financing, Q3 2026 earnings, biosimilar product launches, FDA decisions, and the securities investigation announced in July 2026. Each catalyst can drive discrete moves.
Size positions for binary event risk around acquisition close, FDA, and earnings dates. Avoid concentrating exposure ahead of events where the outcome is highly uncertain.
Investment research summary
Customers pay Amneal for affordable generic medicines, complex injectables, and branded specialty therapies, mainly in neurology (CREXONT, Rytary, UNITHROID), with biosimilars planned as a new growth vertical through the Kashiv acquisition.
Barriers include manufacturing scale in the US, Ireland, and India, a portfolio of about 300 products, FDA-approved facilities, regulatory expertise, and buyer relationships across retail, institutional, and government channels. Generic competition narrows moats over time.
The thesis fails if generic pricing pressure accelerates, the Kashiv biosimilars acquisition is delayed or proves dilutive, CREXONT or Rytary faces unexpected competition, interest costs stay high despite the repricing, or share dilution toward 340 million shares erodes per-share earnings.
Founder co-CEOs Chirag and Chintu Patel have run the company since 2002. The 2026 record includes a Q2 beat, a second guidance raise, a term loan repricing with about $12 million in annual interest savings, and a move into biosimilars, reflecting active capital allocation that still carries integration risk.
The generic pharmaceutical industry benefits from US healthcare cost-containment, an aging population, and rising biosimilar adoption, but faces ongoing pricing headwinds, consolidation, FDA scrutiny, and tariff and supply-chain risk.
At $18.32, the stock trades near 18x forward EPS with FY2026 adjusted EPS guided to $0.96 to $1.06 and FY2027 consensus near $1.16. The margin of safety depends on whether biosimilar execution and debt reduction turn operating momentum into per-share earnings growth that justifies the current multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Q2 2026 revenue and adjusted EPS | $796.2M revenue (+10% YoY), adjusted diluted EPS of $0.30 versus $0.23 consensus | Amneal Q2 2026 press release and StockStory earnings recap | August 3, 2026 |
| Q2 2026 GAAP results | GAAP net income attributable to Amneal of $58M, diluted EPS of $0.18, adjusted EBITDA of $206M | Amneal Q2 2026 press release | August 3, 2026 |
| H1 2026 results | $1,518.7M revenue, $119.9M net income attributable to Amneal, diluted EPS of $0.37 | Amneal Q2 2026 press release | August 3, 2026 |
| Raised FY2026 guidance | Revenue $3.10B to $3.20B, adjusted EBITDA $750M to $780M, adjusted EPS $0.96 to $1.06 | Amneal Q2 2026 press release | August 3, 2026 |
| Debt repricing and leverage goal | $2.084B Term Loan B repriced from SOFR plus 300 bps to plus 250 bps, about $12M annual interest savings, net leverage below 3.0x by 2028 | Amneal Q2 2026 press release | August 3, 2026 |
| Price and market data | $18.32 close on July 31, 2026, market cap of $5.84B, 319.02M shares outstanding | StockAnalysis AMRX overview and statistics | August 3, 2026 |
| Valuation ratios | Trailing PE of 38.1, forward PE of 18.0, EV of about $8.51B, EV/EBITDA of 13.13 | StockAnalysis AMRX statistics | August 3, 2026 |
| FY2025 full-year results | $3.02B revenue and $72.06M GAAP net income, versus FY2023 revenue of $2.39B and a net loss | StockAnalysis AMRX forecast history, S&P Global | August 3, 2026 |
| Technical indicators | 50-day moving average near $16.06, 200-day near $13.48, RSI near 61, 20-day average volume near 1.85M | StockAnalysis AMRX statistics | August 3, 2026 |
| 52-week range and performance | 52-week range of $7.66 to $19.26, 52-week price change of about +127%, YTD gain of about 45% | Yahoo Finance AMRX and MarketBeat AMRX | August 3, 2026 |
| Analyst consensus and price targets | Consensus Buy with an average target near $20.25 (low $16, high $23); Goldman Sachs $21, UBS $23, Piper Sandler $17, Barclays $16 | StockAnalysis AMRX forecast, S&P Global and TipRanks | August 3, 2026 |
| Balance sheet and liquidity | $127.6M cash, about $2.79B total debt, net cash of -$2.66B, current ratio of 2.20 | StockAnalysis AMRX statistics and Amneal Q2 2026 press release | August 3, 2026 |
This AMRX page is an informational research tool, not investment advice or a recommendation to buy or sell. Forecasts are scenarios built from available data and assumptions, can be wrong, and should be checked against current company filings and market conditions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
